Menu Search
Equities

Enzo Biochem Inc

EZB:BER

Enzo Biochem Inc

Actions
  • Price (EUR)1.03
  • Today's Change-0.01 / -0.96%
  • Shares traded--
  • 1 Year change-16.26%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 07:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Enzo Biochem, Inc. is focused on molecular diagnostics and has a portfolio of technical platforms and reagent sets supporting a diverse range of biomedical research and translational science needs. The Company operates through the product segment, which manufactures, develops and markets products and tools for clinical research, translational research, drug development and bioscience research customers worldwide. The Company is engaged in product development and manufactures and supplies a comprehensive portfolio of products, including antibodies, genomic probes, assays, biochemicals and proteins. The Company's products and technologies are used in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry and small molecule chemistry. Its life science division supports the work of research centers and industry partners. It has built a portfolio of intellectual property assets, comprised of around 457 owned patents worldwide.

  • Revenue in USD (TTM)31.91m
  • Net income in USD-9.82m
  • Incorporated1976
  • Employees125.00
  • Location
    Enzo Biochem Inc60 EXECUTIVE BLVDFARMINGDALE 11735United StatesUSA
  • Phone+1 (516) 755-5500
  • Websitehttps://www.enzo.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.